Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro

The American Journal of Medicine
O G KoltermanJ M Olefsky

Abstract

The insulin resistance associated with NIDDM appears to be caused by decreased insulin binding in conjunction with a significant postreceptor defect in insulin action. In the untreated state, the postreceptor defect appears to be the predominant lesion and the magnitude of this postreceptor defect appears to correlate directly with the degree of fasting hyperglycemia in individual patients. In vitro studies using isolated adipocytes suggest that the postreceptor defect in insulin action resides at the level of the glucose transport system. Insulin treatment ameliorates the postreceptor defect in insulin action which suggests that it is an acquired defect secondary to some aspect of the altered metabolic state. Therapy with the second-generation sulfonylurea compound glyburide enhances overall insulin responsiveness without altering insulin binding. Prevailing insulin levels are increased markedly during glyburide therapy but do not correlate with the clinical response, which suggests that the improvement in target tissue insulin action is the critical determinant in terms of the clinical response to the drug. In vitro studies utilizing cultured human fibroblasts indicate that glyburide increases the number of cell-surface insul...Continue Reading

References

Aug 1, 1976·The Journal of Cell Biology·C R Kahn
Apr 1, 1976·The New England Journal of Medicine·C R KahnJ Roth
Jan 1, 1977·Annual Review of Biochemistry·M P Czech
May 1, 1978·Diabetes Care·H E Lebovitz, M N Feinglos
May 1, 1979·The Journal of Clinical Investigation·R DeFronzoV Soman
Sep 13, 1979·Nature·H TagerR Poucher
Jan 1, 1978·Advances in Metabolic Disorders·G M Reaven, J M Olefsky
Jan 1, 1979·The Journal of Clinical Endocrinology and Metabolism·M MuggeoP Gorden
May 25, 1978·The New England Journal of Medicine·R S BarM Muggeo
Jan 1, 1976·The American Journal of Medicine·G M ReavenJ M Olefsky
Apr 22, 1976·The New England Journal of Medicine·K H GabbayA H Rubenstein
Mar 1, 1975·The Journal of Clinical Investigation·H GinsbergG M Reaven
Jan 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·J R GavinD N Buell
Dec 1, 1974·The Journal of Clinical Investigation·J M Olefsky, G M Reaven
Oct 1, 1972·The Journal of Clinical Endocrinology and Metabolism·W C DuckworthA E Kitabchi
Jul 1, 1982·Diabetes Care·J A ScarlettO G Kolterman
Sep 1, 1980·The Journal of Clinical Investigation·M J Prince, J M Olefsky
Feb 1, 1981·The American Journal of Medicine·T G Skillman, J M Feldman
Jan 1, 1980·Annual Review of Medicine·H S Seltzer
Jun 1, 1980·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Jan 1, 1981·The American Journal of Medicine·J M Olefsky, O G Kolterman
Oct 1, 1981·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Nov 1, 1981·Endocrinology·M J PrinceJ M Olefsky
Jan 17, 1980·The New England Journal of Medicine·B D GivenR Poucher
Jul 1, 1995·The National Medical Journal of India·A Misra

❮ Previous
Next ❯

Citations

Mar 7, 2001·European Journal of Medicinal Chemistry·M S MalamasD Sullivan
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·K M TordjmanM M Mueckler
Feb 2, 2008·Chemical & Pharmaceutical Bulletin·Khalid RasheedHamid Latif Siddiqui
Jul 1, 1985·Mayo Clinic Proceedings·J E Gerich
Nov 30, 1983·The American Journal of Medicine·D H Lockwood, J M Amatruda
Jul 1, 1987·Diabetic Medicine : a Journal of the British Diabetic Association·C B Hollenbeck, G M Reaven
Dec 1, 2009·BMC Complementary and Alternative Medicine·Hemant PareekG C Jain
Oct 1, 1990·Diabetes Research and Clinical Practice·J Cederholm, L Wibell
Dec 8, 2004·Bioorganic & Medicinal Chemistry Letters·José A MartínAlan M Warshawsky
Oct 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·H Beck-NielsenO Pedersen
Oct 1, 1992·Diabetes/metabolism Reviews·E Shafrir
Jan 2, 2001·Endocrine Reviews·S MatthaeiH U Häring
Dec 19, 1996·Chemical Reviews·George A. Patani, Edmond J. LaVoie
Aug 1, 1989·Diabetes Research and Clinical Practice·M KofflerP Raskin
May 1, 1986·Pharmacological Research Communications·R I Hoich, F M Ng
May 30, 1998·Journal of Medicinal Chemistry·B B LohrayS Subramaniam
May 28, 2003·Journal of Chemical Information and Computer Sciences·S J Patankar, P C Jurs

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.